F. Higashi

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation

Emanuella G Souza, V. Hungria, Â. Maiolino, 2019, Hematology, transfusion and cell therapy.

Bilateral breast plasmacytoma: a clinical case report

V. Hungria, E. Crusoé, Thais Fischer, 2016, Revista brasileira de hematologia e hemoterapia.

Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life

V. Hungria, E. Crusoé, M. Lopes, 2022, Hematology, transfusion and cell therapy.

Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?

V. Hungria, E. Crusoé, C. Chiattone, 2016, Revista brasileira de hematologia e hemoterapia.

Multiple myeloma and central nervous system involvement: experience of a Brazilian center

V. Hungria, E. Crusoé, F. Higashi, 2017, Revista brasileira de hematologia e hemoterapia.

Outcomes of autologous transplantation for multiple myeloma according to different induction regimens

E. Miranda, M. Almeida, C. Chiattone, 2014, Revista brasileira de hematologia e hemoterapia.

[Not Available].

E. Miranda, M. Almeida, C. Chiattone, 2014, Revista brasileira de hematologia e hemoterapia.

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients

V. Hungria, E. Crusoé, F. Zacchi, 2019, Hematology, transfusion and cell therapy.